We warranted the combined use of drugs targeting SNRPD1 and anthracycline type of chemotherapies in breast cancer management that may generate undesirable therapeutic outcome as targeting SNRPD1 triggered the resistance of TNBC cells to doxorubicin. The gene discussed is SNRPD1; the disease is breast carcinoma.